These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8382073)

  • 21. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma.
    Sheikh MS; Shao ZM; Li XS; Ordonez JV; Conley BA; Wu S; Dawson MI; Han QX; Chao WR; Quick T
    Carcinogenesis; 1995 Oct; 16(10):2477-86. PubMed ID: 7586155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
    Alkner S; Bendahl PO; Fernö M; Nordenskjöld B; Rydén L;
    Eur J Cancer; 2009 Sep; 45(14):2496-502. PubMed ID: 19535242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerability.
    Mariani L; Formelli F; De Palo G; Manzari A; Camerini T; Campa T; Di Mauro MG; Crippa A; Delle Grottaglie M; Del Vecchio M; Marubini E; Costa A; Veronesi U
    Tumori; 1996; 82(5):444-9. PubMed ID: 9063520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
    Formelli F
    J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoprevention of breast cancer.
    Costa A; Sacchini V; Bonanni B; D'Aiuto G
    Eur J Cancer Prev; 1994 Jul; 3(4):361-4. PubMed ID: 7950891
    [No Abstract]   [Full Text] [Related]  

  • 26. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
    Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
    Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined effect of tamoxifen or interferon-beta and 4-hydroxyphenylretinamide on the growth of breast cancer cell lines.
    Coradini D; Biffi A; Pellizzaro C; Pirronello E; Di Fronzo G
    Tumour Biol; 1997; 18(1):22-9. PubMed ID: 8989922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial.
    Torrisi R; Mezzetti M; Johansson H; Barreca A; Pigatto F; Robertson C; Decensi A
    Int J Cancer; 2000 Aug; 87(4):601-5. PubMed ID: 10918204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adiponectin: a risk biomarker and attractive target for chemoprevention.
    Fabian CJ
    J Clin Oncol; 2012 Jan; 30(2):124-6. PubMed ID: 22162567
    [No Abstract]   [Full Text] [Related]  

  • 30. Preventive therapy for breast cancer: a consensus statement.
    Cuzick J; DeCensi A; Arun B; Brown PH; Castiglione M; Dunn B; Forbes JF; Glaus A; Howell A; von Minckwitz G; Vogel V; Zwierzina H
    Lancet Oncol; 2011 May; 12(5):496-503. PubMed ID: 21441069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
    Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
    J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
    Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
    Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fenretinide and risk reduction of second breast cancer.
    Decensi A; Zanardi S; Argusti A; Bonanni B; Costa A; Veronesi U
    Nat Clin Pract Oncol; 2007 Feb; 4(2):64-5. PubMed ID: 17259924
    [No Abstract]   [Full Text] [Related]  

  • 35. Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
    Ménard S; Camerini T; Mariani L; Tomasic G; Pilotti S; Costa A; De Palo G; Veronesi U
    J Natl Cancer Inst; 2001 Feb; 93(3):240-1. PubMed ID: 11158198
    [No Abstract]   [Full Text] [Related]  

  • 36. [-Results of ongoing breast cancer prevention studies-].
    Jungi WF
    Arch Gynecol Obstet; 1995; 256 Suppl():S116-21. PubMed ID: 8619644
    [No Abstract]   [Full Text] [Related]  

  • 37. Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide.
    Johansson H; Bonanni B; Gandini S; Guerrieri-Gonzaga A; Cazzaniga M; Serrano D; Macis D; Puccio A; Sandri MT; Gulisano M; Formelli F; Decensi A
    Breast Cancer Res Treat; 2013 Dec; 142(3):569-78. PubMed ID: 24241787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast cancer chemoprevention: additional observations.
    Singh-Ranger G; Mokbel K
    Int J Clin Pract; 2003 Mar; 57(2):155; author reply 155. PubMed ID: 12661805
    [No Abstract]   [Full Text] [Related]  

  • 39. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium.
    Kurie JM; Lee JS; Khuri FR; Mao L; Morice RC; Lee JJ; Walsh GL; Broxson A; Lippman SM; Ro JY; Kemp BL; Liu D; Fritsche HA; Xu X; Lotan R; Hong WK
    Clin Cancer Res; 2000 Aug; 6(8):2973-9. PubMed ID: 10955773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.
    De Palo G; Camerini T; Marubini E; Costa A; Formelli F; Del Vecchio M; Mariani L; Miceli R; Mascotti G; Magni A; Campa T; Di Mauro MG; Attili A; Maltoni C; Del Turco MR; Decensi A; D'Aiuto G; Veronesi U
    Tumori; 1997; 83(6):884-94. PubMed ID: 9526578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.